

TARGET[®] First

Focused | Fast | Affordable.

Comprehensive Profiling of Solid Tumors Using Tissue, Liquid Biopsy (First Liquid), or a Combined Approach (First SoLiQ).
Quick Turnaround, Ideal for First-line Use.



CGP Testing for All Solid Cancers at an Affordable Price

PRECISION DETECTION OF HIGH-IMPACT ACTIONABLE GENOMIC ALTERATIONS.

WHY TARGET FIRST?



Comprehensive Yet Focused:

- Covers 92 clinically relevant cancer-associated genes with established evidence in Precision Oncology for newly diagnosed or locally advanced diseases
- Designed to capture the most actionable genomic alterations across solid tumors while maintaining affordability



Targeted Therapy & Predictive Biomarkers:

- Identifies clinically actionable alterations linked to FDA-approved, NCCN-recommended, and emerging targeted therapies from 87 SNVs/Indels, 72 CNAs and 11 DNA level Gene-fusions
- Supports treatment selection and therapeutic stratification across multiple solid cancers



Prognostic Insights:

- Detects genomic biomarkers associated with disease progression, recurrence risk, treatment resistance, and overall prognosis, enabling informed clinical decision-making



Pharmacogenomic Intelligence:

- Evaluates key biomarkers that may influence drug response, efficacy, and toxicity, helping optimize personalized treatment strategies



Tissue-Agnostic Biomarker Coverage:

- Includes clinically important biomarkers that support tumor-agnostic treatment approaches, expanding therapeutic opportunities beyond tumor type



Designed for Routine Precision Oncology:

- Focused panel architecture enables rapid turnaround, high-depth sequencing, & cost-effective comprehensive biomarker assessment over sequential single gene based assays



Flexible Sample Compatibility:

- Supports both Tissue Biopsy (FFPE) and Liquid Biopsy (ctDNA) samples, with the option of an integrated SoLiQ[®] (Solid + Liquid Biopsy) approach to maximize biomarker detection, overcome individual sample limitations, and provide a more comprehensive assessment of tumor heterogeneity and disease biology with baseline insights from both the sources

Key Genes in TARGT First Associated with Therapeutic Options



92 GENES PANEL

● SNVs/InDels : 87
▲ CNAs : 72
■ Gene Fusions: 11

ABL1	● ▲	FANCA	● ▲	NBN	● ▲	RAD50	● ▲
AKT1	● ▲	FANCL	● ▲	NF1	● ▲	RAD51	● ▲
ALK	● ▲ ■	FGFR1	● ▲	NF2	● ▲	RAD51B	● ▲
APC	● ▲	FGFR2	● ▲ ■	NRAS	● ▲	RAD51C	● ▲
AR	● ▲	FGFR3	● ▲ ■	NRG1*	■	RAD51D	● ▲
ATM	● ▲	FGFR4	● ▲	NRG2*	■	RAD54L	● ▲
ATR	● ▲	GAPDH	● ▲	NTRK1	■	RB1	● ▲
BARD1	● ▲	H3-3A	●	NTRK2*	■	RET	● ▲ ■
BMPR1A	● ▲	H3C2	●	NTRK3*	■	ROS1	● ▲ ■
BRAF	● ▲	HRAS	● ▲	PALB2	● ▲	SMAD4	● ▲
BRCA1	● ▲	IDH1	●	PDGFRA	● ▲	STK11	● ▲
BRCA2	● ▲	IDH2	● ▲	PDGFRAB	▲	TP53	● ▲
BRIP1	● ▲	JAK2	● ▲	PDGFRB	●	TSC1	● ▲
CCND1	● ▲	KIT	● ▲	PIK3CA	●	TSC2	● ▲
CDK12	● ▲	KRAS	●	PMS1	●	TERT	● ▲
CDK4	● ▲	MAP2K1	●	PMS2	●	TPMT	● ▲
CDK6	● ▲	MAP2K2	●	POLD1	● ▲	UGT1A1	● ▲
CDKN2A	● ▲	MDM2	● ▲	POLE	● ▲		
CHEK1	● ▲	MET	● ▲ ■	POLH	● ▲		
CHEK2	● ▲	MLH1	● ▲	PTEN	● ▲		
CTNNB1	● ▲	MLH3	●	PIK3R1	● ▲		
DPYD	● ▲	MRE11 (MRE11A)	● ▲				
EGFR	● ▲	MSH2	●				
EPCAM	● ▲	MSH6	●				
ERBB2	● ▲	MUTYH	● ▲				
ERBB3	● ▲						
ERBB4	● ▲						
ESR1	●						
EZH2	● ▲						

* **NOTE 1** - The scope of test includes the most common gene fusions for NRG1, NRG2, NTRK2 and NTRK3 with different transcripts - NACC2-NTRK2, TRIM24-NTRK2, QKI-NTRK2, BTBD1-NTRK3, EML4-NTRK3, ETV6-NTRK3, CD74-NRG1, SDC4-NRG1 & CD74-NRG2

NOTE 2 - High sensitivity and specificity in detecting low frequency genomic alterations - Accuracy 100% for SNVs, INDELS, CNAs and fusions at as low as 5% mutant allele frequency even for low quality FFPE samples.

Assay Specification and Performance Overview



Gene Number

92 Genes



Sample Type

FFPE Tissue block ideally not more than 5 months old,
Fresh Frozen Tissue, with > 20% Tumor content,
2x10ml blood in Streck Tube



Specificity and Sensitivity

99.99%



Turn Around Time

12-14 working days



Sequencing Chemistry

Hybrid Capture, End to End Sequencing
of all the Exons of a given Gene



Mean Sequencing Depth

2000X for Tissue, 20,000X
for Liquid Biopsy, 20,000X
for Tissue and Liquid
Combined

Revolutionising Care, Personalising Hope Globally

With Precision Oncology, we're not just treating cancer.
We're redefining what's possible in Cancer care.

Together, **We Beat** Cancer



● India ● Nepal ● Philippines ● UAE



For any further information on 4baseCare Solutions and Services, please contact:

 4basecare.com

 +91 636-684-3415

 info@4basecare.com

 3rd floor, Summit B, Brigade Metropolis, Garudachar Palya, Bengaluru, Karnataka 560048